Kiora Pharmaceuticals Net Worth
Kiora Pharmaceuticals Net Worth Breakdown | KPRX |
Kiora Pharmaceuticals Net Worth Analysis
Kiora Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Kiora Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Kiora Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Kiora Pharmaceuticals' net worth analysis. One common approach is to calculate Kiora Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Kiora Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Kiora Pharmaceuticals' net worth. This approach calculates the present value of Kiora Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Kiora Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Kiora Pharmaceuticals' net worth. This involves comparing Kiora Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Kiora Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Kiora Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Kiora Pharmaceuticals' net worth research are outlined below:
| Kiora Pharmaceuticals generated a negative expected return over the last 90 days | |
| Kiora Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (12.51 M) with loss before overhead, payroll, taxes, and interest of (5.14 M). | |
| Kiora Pharmaceuticals currently holds about 2.43 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64. | |
| Kiora Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Shapiro Aron of 5000 shares of Kiora Pharmaceuticals at 0.5677 subject to Rule 16b-3 |
Kiora Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Kiora Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kiora Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Kiora Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kiora Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiora Pharmaceuticals backward and forwards among themselves. Kiora Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kiora Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-06-30 | 20.0 | U.s. Bancorp | 2024-06-30 | 8.0 | Activest Wealth Management | 2024-06-30 | 3.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.0 | Jpmorgan Chase & Co | 2024-06-30 | 1.0 | Captrust Financial Advisors | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 | Two Sigma Investments Llc | 2024-06-30 | 0.0 | Aigh Capital Management, Llc | 2024-09-30 | 255.6 K | Nantahala Capital Management, Llc | 2024-09-30 | 211.1 K |
Follow Kiora Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.75 M.Market Cap |
|
Project Kiora Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.55) | (2.68) | |
| Return On Capital Employed | (1.04) | (0.99) | |
| Return On Assets | (0.91) | (0.96) | |
| Return On Equity | (2.05) | (1.95) |
When accessing Kiora Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Kiora Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Kiora Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Kiora Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kiora Pharmaceuticals. Check Kiora Pharmaceuticals' Beneish M Score to see the likelihood of Kiora Pharmaceuticals' management manipulating its earnings.
Evaluate Kiora Pharmaceuticals' management efficiency
Kiora Pharmaceuticals has return on total asset (ROA) of 0.1296 % which means that it generated a profit of $0.1296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1369 %, meaning that it created $0.1369 on every $100 dollars invested by stockholders. Kiora Pharmaceuticals' management efficiency ratios could be used to measure how well Kiora Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.68 in 2024. Return On Capital Employed is likely to rise to -0.99 in 2024. At this time, Kiora Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 5.6 M in 2024, whereas Total Assets are likely to drop slightly above 11.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.36 | 11.92 | |
| Tangible Book Value Per Share | (5.03) | (5.28) | |
| Enterprise Value Over EBITDA | (0.01) | (0.02) | |
| Price Book Value Ratio | 0.41 | 0.43 | |
| Enterprise Value Multiple | (0.01) | (0.02) | |
| Price Fair Value | 0.41 | 0.43 | |
| Enterprise Value | 180.8 K | 171.8 K |
The strategic initiatives led by Kiora Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 569.4141 | Revenue 16 M | Revenue Per Share 7.424 | Return On Equity 0.1369 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kiora Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kiora Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kiora Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kiora Pharmaceuticals Corporate Filings
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Kiora Pharmaceuticals Earnings per Share Projection vs Actual
Kiora Pharmaceuticals Corporate Management
| MD MBA | Chief Officer | Profile | |
| Brian Strem | CEO and President | Profile | |
| Melissa Tosca | Ex Fin | Profile | |
| Stefan Sperl | Executive Operations | Profile | |
| MaryJane Rafii | Consultant | Profile | |
| Melissa CPA | Executive Finance | Profile |
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.